title: Brinzolamide-timolol fixed combination for the prevention of intraocular pressure elevation after phacoemulsification.
abstract: BACKGROUND
  To evaluate the efficacy of brinzolamide-timolol fixed combination in intraocular pressure during the first 24 h after uneventful phacoemulsification cataract surgery using Viscoat and Provisc.
  
  
  METHODS
  Prospective randomized comparative case series.
  
  
  METHODS
  Ninety-two eyes of equal patients scheduled for phacoemulsification cataract surgery.
  
  
  METHODS
  Treatment group (52 eyes) received a drop of brinzolamide-timolol fixed combination immediately after surgery. Control group (40 eyes) received no treatment.
  
  
  METHODS
  Intraocular pressure preoperatively and at 6, 12 and 24 h postoperatively.
  
  
  RESULTS
  Six hours after surgery the mean intraocular pressure decreased by 0.3 ± 2.95 mmHg (P > 0.05) in the treatment group and increased by 6.8 ± 2.78 mmHg (P < 0.001) in the control group. Twelve hours postoperatively, the mean intraocular pressure increased by 0.23 ± 3.49 mmHg (P > 0.05) in the treatment group and by 5.3 ± 3.26 mmHg (P < 0.001) in the control group. Twenty-four hours after surgery, the mean intraocular pressure decreased by 1.76 ± 2.83 mmHg (P < 0.01) in the treatment group and in the control group increased by 1.4 ± 2.46 mmHg (P > 0.05). The intraocular pressure in the treatment group was statistically significantly lower compared with the control group at 6, 12 and 24 h postoperatively. None of the eyes in the treatment group had postoperative intraocular pressure elevation ≥10 mmHg; such an increase was recorded in 20% and 10% of control eyes at 6 and 12 h after surgery, respectively.
  
  
  CONCLUSIONS
  A single dose of brinzolamide-timolol fixed combination after phacoemulsification cataract surgery prevented a significant intraocular pressure increase during the first 24 h postoperatively.
authors: Department of Ophthalmology, University of Patras Medical School, Patras, Greece.
authors: Constantine D
authors: CD
authors: Georgakopoulos
authors: Olga E
authors: OE
authors: Makri
authors: Panagiotis
authors: P
authors: Plotas
authors: Nikolaos
authors: N
authors: Pharmakakis
mesh_terms: D000368:Aged; D000369:Aged, 80 and over; D000959:Antihypertensive Agents / Q000627:therapeutic use; D002257:Carbonic Anhydrase Inhibitors / Q000627:therapeutic use; D004311:Double-Blind Method; D004338:Drug Combinations; D005260:Female; D006801:Humans; D007429:Intraocular Pressure / Q000187:drug effects*; D019654:Lens Implantation, Intraocular; D008297:Male; D008875:Middle Aged; D009798:Ocular Hypertension / Q000517:prevention & control*; D009883:Ophthalmic Solutions; D018918:Phacoemulsification; D011183:Postoperative Complications / Q000517:prevention & control*; D011446:Prospective Studies; D013449:Sulfonamides / Q000627:therapeutic use*; D013843:Thiazines / Q000627:therapeutic use*; D013999:Timolol / Q000627:therapeutic use*; D014065:Tonometry, Ocular; D055675:Viscosupplements
chemical_list: D000959:Antihypertensive Agents; D002257:Carbonic Anhydrase Inhibitors; D004338:Drug Combinations; D009883:Ophthalmic Solutions; D013449:Sulfonamides; D013843:Thiazines; D055675:Viscosupplements; D013999:Timolol; C111827:brinzolamide
keywords: brinzolamide-timolol; fixed combination; intraocular pressure; phacoemulsification